Investigation of the role of conserved serine residues in the long form of the rat D2 dopamine receptor using site-directed mutagenesis

Journal of Neurochemistry

Volumn 66, Issue 1, 1996, Pages 394-402

  Woodward, R ^a   Coley, C ^a   Daniell, S ^a   Naylor, L H ^a   Strange, P G ^a  

^a UNIVERSITY OF KENT   (United Kingdom)

Author keywords

Agonist; Antagonist; D2 dopamine receptor; Hydrogen bond; Mutagenesis; Serine

Indexed keywords

DOPAMINE 2 RECEPTOR;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; GENE MUTATION; HYDROGEN BOND; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RAT; SITE DIRECTED MUTAGENESIS;

ANIMALIA;

EID: 0030053844     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1996.66010394.x     Document Type: Article

References (20)

1. 2 dopamine receptor. J. Neurochem. 60, 372-375.
2. Civelli O., Bunzow J. R., and Grandy D. K. (1993) Molecular diversity of the dopamine receptors. Annu. Rev. Pharmacol. Toxicol. 32, 281-307.
3. 2 receptors. J. Neurochem. 59, 627-635.
4. De Lean A., Stadel J. M., and Lefkowitz R. J. (1980) A ternary complex model explains the agonist specific binding properties of the adenylate cyclase coupled β-adrenergic receptor. J. Biol. Chem 255, 7108-7117.
5. Fersht A. R., Shi P. J., Knill-Jones J., Lowe D. M., Wilkinson A. J., Blow D. M., Brick P., Carter P., Waye M. M., and Winter G. (1985) Hydrogen bonding and biological specificity analysed by protein engineering. Nature 314, 235-238.
6. Fraser C. M., Wang C. D., Robinson D A., Gocayne J. D., and Venter J. C. (1989) Site-directed mutagenesis of muscarinic m1 receptors; conserved aspartic acid residues play important roles in receptor function. Mol. Pharmacol. 36, 840-847.
7. 2-receptor antagonists. Drugs Future 16, 333-357.
8. Hulme E. C., Curtis C. A. M., Page K. M., and Jones P. G. (1993) Agonist activation of muscarinic acetylcholine receptors. Cell. Signal. 5, 687-694.
9. Lefkowitz R. J., Cottechia S., Samama P., and Costa T. (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol. Sci. 14, 303-307.
10. Livingstone C. D., Strange P. G., and Naylor L. H. (1992) Molecular modelling of D2, D3 and D4 dopamine receptors. Biochem. J. 287, 277-282.
11. Malmberg A., Jackson D. M., Eriksson A., and Mohell N. (1993) Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B and D3 dopamine receptors. Mol. Pharmacol. 43, 749-754.
12. 2 receptor. Eur. J. Pharmacol. 227, 205-214.
13. Pollock N. J., Manelli A. M., Hutchins C. W., Steffey M. E., Mac-Kenzie R. G., and Frail D. E. (1992) Mutations in transmembrane V of the dopamine D1 receptor affect ligand interactions and receptor activation. J. Biol. Chem. 267, 17780-17786.
14. Seeman P. (1980) Brain dopamine receptors. Pharmacol. Rev. 32, 229-313.
15. 2 receptor binding sites for agonists. Mol. Pharmacol. 28, 391-399.
16. Strader C. D., Sigal I. S., Candelore M. R., Rands E., Hill W. S., and Dixon R. A. F. (1988) Conserved aspartic acid residues 79 and 113 of the β-adrenergic receptor have different roles in receptor function. J. Biol. Chem. 263, 10267-10271.
17. Strader C. D., Candelore M. R., Hill W. S., Sigal I. S., and Dixon R. A. F. (1989) Identification of two serine residues involved in agonist activation of the β-adrenergic receptor. J. Biol. Chem. 264, 13572-13578.
18. 2A-adrenergic receptors: identification of amino acids involved in ligand binding and receptor activation by agonists. Mol. Pharmacol. 40, 168-179.
19. 2 dopamine receptors: mutation of a histidine residue specifically affects the binding of a subgroup of substituted benzamide drugs. J. Neurochem. 62, 1664-1669.
20. Wreggett K. and De Lean A. (1984) The ternary complex model. Mol. Pharmacol. 26, 214-227.